Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncology drugs specialist EpiCept Corp. has said that a Phase I clinical trial for EPC2407, a small molecule vascular disruption agent and apoptosis inducer for the treatment of advanced solid tumors and lymphomas, met all of its objectives.
Subscribe to our email newsletter
EpiCept successfully identified the maximum tolerated dose of EPC2407 in the Phase I study. The maximum tolerated dose was well below the dose which produced the expected toxicity based on preclinical studies at higher doses. EPC2407 was administered as a single agent in increasing doses to small cohorts of patients with advanced solid tumors.
A total of seventeen patients were enrolled in the study. The drug was tested in a variety of cancer types including melanoma, prostate, lung, breast, colon, and pancreatic cancers. The study, which was initiated in December 2006, was conducted at three cancer centers in the U.S.
Jack Talley, president and CEO of EpiCept said: “We are pleased that this milestone has been reached. We are now in the process of meeting with our advisors to move forward with a Phase Ib combination trial for the drug with other chemotherapeutic agents.”